Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

医学 内科学 中止 安慰剂 临床终点 中期分析 人口 耐受性 意向治疗分析 无进展生存期 临床试验 化疗 不利影响 环境卫生 病理 替代医学
作者
Jianming Xu,Lin Shen,Chunmei Bai,Wei Wang,Jie Li,Xianjun Yu,Zhiping Li,Enxiao Li,Xianglin Yuan,Yihebali Chi,Yongmei Yin,Wenhui Lou,Nong Xu,Yuxian Bai,Tao� Zhang,Dianrong Xiu,Xiuwen Wang,Ying Yuan,Jia Chen,Shukui Qin
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (11): 1489-1499 被引量:207
标识
DOI:10.1016/s1470-2045(20)30493-9
摘要

Background Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumours (NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the efficacy and safety of surufatinib in patients with advanced pancreatic NETs. Methods SANET-p was a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, done in 21 hospitals across China. Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease. Patients were randomly assigned (2:1) via an interactive web response system to receive 300 mg of surufatinib or placebo, taken orally once per day in consecutive 4-week treatment cycles until disease progression, intolerable toxicity, withdrawal of consent, poor compliance, use of other antitumour medication, pregnancy, loss to follow-up, or if the investigator deemed discontinuation in the patient's best interest. Randomisation was done centrally using stratified block randomisation (block size three), stratified by pathological grade, previous systemic antitumour treatment, and ECOG performance status score. Patients, investigators, research staff, and the sponsor study team were masked to treatment allocation. Crossover to surufatinib was permitted for patients in the placebo group with disease progression. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population, which included all patients in randomisation. A pre-planned interim analysis was done at 70% of the predicted progression-free survival events. This study is registered at ClinicalTrials.gov, NCT02589821. Findings Between Feb 18, 2016, and Nov 11, 2019, of 264 patients who were screened, 172 (65%) patients were randomly assigned to receive surufatinib (n=113) or placebo (n=59). The median follow-up was 19·3 months (95% CI 9·3–19·4) in the surufatinib group and 11·1 months (5·7–35·9) in the placebo group. The median investigator-assessed progression-free survival was 10·9 months (7·5–13·8) for surufatinib versus 3·7 months (2·8–5·6) for placebo (hazard ratio 0·49, 95% CI 0·32–0·76; p=0·0011). The trial met the early stopping criteria at the interim analysis and was terminated on recommendation from the independent data monitoring committee. The most common grade 3 or worse treatment-related adverse events were hypertension (43 [38%] of 113 with surufatinib vs four [7%] of 59 with placebo), proteinuria (11 [10%] vs one [2%]), and hypertriglyceridaemia (eight [7%] vs none). Treatment-related serious adverse events were reported in 25 (22%) patients in the surufatinib group and four (7%) patients in the placebo group. There were three on-treatment deaths in the surufatinib group, including two deaths due to adverse events (gastrointestinal haemorrhage [possibly treatment-related] and cerebral haemorrhage [unlikely to be treatment-related]), and one death attributed to disease progression. One on-treatment death in the placebo group was attributed to disease progression. Interpretation Surufatinib significantly improves progression-free survival and has an acceptable safety profile in patients with progressive, advanced pancreatic NETs, and could be a potential treatment option in this patient population. Funding Hutchison MediPharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我是老大的应助被传统的阙德采纳,获得10
刚刚
syy发布了新的文献求助10
刚刚
丘比特的应助被王小牛仔采纳,获得10
2秒前
完美世界的应助被于66采纳,获得10
3秒前
3秒前
我是老大的应助被小李采纳,获得10
4秒前
4秒前
1618发布了新的文献求助30
5秒前
大个的应助被YYLLTX采纳,获得10
5秒前
5秒前
FashionBoy的应助被时尚篮球采纳,获得10
6秒前
苗条世界完成签到,获得积分10
7秒前
鸥羡发布了新的文献求助10
7秒前
捏鱼发布了新的文献求助10
8秒前
科研通AI2S的应助被假发君采纳,获得10
9秒前
有个女孩叫阿娇完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
顺利的蛋挞完成签到,获得积分10
11秒前
12秒前
12秒前
东门吹雪完成签到,获得积分10
12秒前
regina完成签到,获得积分20
14秒前
14秒前
余香的应助被jay8696采纳,获得10
14秒前
16秒前
Ting发布了新的文献求助10
16秒前
16秒前
盈虚者发布了新的文献求助10
16秒前
汉堡包的应助被醒醒采纳,获得10
16秒前
sunsuan发布了新的文献求助10
16秒前
lx20021111完成签到,获得积分10
17秒前
蓝月发布了新的文献求助30
17秒前
于66发布了新的文献求助10
17秒前
17秒前
18秒前
18秒前
zhy1103完成签到 ,获得积分10
18秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158017
求助须知:如何正确求助?哪些是违规求助? 9553900
关于积分的说明 21716555
捐赠科研通 7747340
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551639
邀请新用户注册赠送积分活动 2471005